Two specialists are impressed by the preliminary findings of a randomized trial in newly diagnosed patients, but another is ...

The incidence of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis increases with age.1 Despite this trend, ...

In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...

This common issue is estimated to affect 5–20 percent of spayed dogs [1] and around 1 percent ... All dogs will originally receive 2 mg by mouth once per day. If effective, the dose is systematically ...

EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Masofaniten plus Enzalutamide Results in Increased rPFS On September ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

As of 2018, the estimated five-year survival rate for distant metastatic (Stage IV) melanoma is 22.5%. KEYTRUDA is an ...